The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

September 9, 2019 • By Anne Harding

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows.

You Might Also Like
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

“The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of fracture,” Joy N. Tsai, MD, of Massachusetts General Hospital and Harvard Medical School, Boston, the study’s first author, tells Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Osteoporosis drugs now available have modest effects on BMD and non-vertebral fracture risk, she and her colleagues note in The Lancet Diabetes and Endocrinology, online Aug. 22.1

In the Denosumab and Teriparatide Administration (DATA) trial, Dr. Tsai and her team found adding teraparatide to denosumab “increased BMD, improved skeletal microarchitecture, and increased estimated bone strength to a greater extent than either drug alone.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The efficacy of this combination is likely to be due to denosumab’s ability to fully block the resorptive effects of teriparatide while possibly allowing for teriparatide-induced stimulation of modelling-based bone formation,” they add.

In DATA-HD, the authors randomized 76 postmenopausal women with osteoporosis to 20 or 40 ug teriparatide for nine months. Three months into the study, all study participants began receiving 60 mg of denosumab every six months for 12 months.

At 15 months, the higher-dose group had a 17.5% mean increase in spine aBMD vs. 9.5% for the lower-dose group (P<0.0001). Femoral neck aBMD increased by 6.8% and 4.3% (P=0.04), respectively, and total hip by 6.1% and 3.9% (P<0.0001), respectively.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Volumetric BMD also showed significantly greater increases with the higher-dose treatment at all sites. Spine strength at 15 months was 33.3% higher with the 40 ug dose versus 18.5% with 20 ug, and mean total hip strength increased by 7.9% and 4.3%, respectively.

“Next steps include physiology-based studies to better understand what makes this particular combination of osteoporosis uniquely efficacious in increasing bone density and potentially a fracture outcome study to further support the clinical value of this regimen,” Dr. Tsai says.

“Using a combination of drugs for osteoporosis, namely teriparatide at twice the FDA-approved dose, along with denosumab actually resulted in greater increases in bone density than either drug alone,” Sundeep Khosla, MD, of the Mayo Clinic College of Medicine, Rochester, Minn., tells Reuters Health by phone. “For patients who are at very high risk of fracture this kind of combination therapy may be an important option.”

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: bone mineral density (BMD), denosumab, Osteoporosis, osteoporosis treatments, teriparatide, teriparatide treatment for osteoporosis

You Might Also Like:
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.